# US 11,110,129 B2 · Method for treating multiple sclerosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,110,129 B2
- Document ID: US11110129B2
- Status: Granted
- Kind: B2
- Application number: 16/353,127
- Filed: 2019-03-14
- Published: 2019-07-04
- Granted: 2021-09-07
- Earliest claimed: 2015-07-22
- Assignees: China Medical University
- Applicants: China Medical University
- Inventors: Woei-Cherng Shyu; Chen-Huan Lin; Wei Lee; Chia-Hung Hsieh; Chung-Y Hsu; Chang-Hai Tsai
- Web page: https://patentgrep.com/patent/US11110129B2

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 38/179: {for growth factors; for growth regulators}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12N 5/0665: {Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood}
- C12N 5/0668: {Mesenchymal stem cells from other natural sources}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- C12N 2500/84: from mammals
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method for treating a multiple sclerosis is provided. The method includes administering a composition containing a plurality of mesenchymal stem cells to a subject in need for a treatment of the multiple sclerosis, in which each of the mesenchymal stem cells expresses insulin-like growth factor 1 receptors.

## Claims

### Claim 1

A method for treating a multiple sclerosis, the method comprising administering a composition containing a plurality of insulin-like growth factor 1 receptor positive umbilical cord mesenchymal stem cells to a subject in need for a treatment of the multiple sclerosis, wherein each of the umbilical cord mesenchymal stem cells is derived from Wharton's jellies and isolated by using an insulin-like growth factor 1 receptor antibody and then cultured in a medium containing platelet-derived growth factor BB (PDGF-BB) at 2.5-50 ng/mL to enhance the expression of insulin-like growth factor 1 receptors in the umbilical cord mesenchymal stem cells, wherein the composition is administered by an intravenous injection.

### Claim 2 (depends on 1)

The method of claim 1, wherein the multiple sclerosis is a relapsing-remitting multiple sclerosis (RRMS).

### Claim 3 (depends on 1)

The method of claim 1, wherein the multiple sclerosis is a primary progressive multiple sclerosis (PPMS).

### Claim 4 (depends on 1)

The method of claim 1, wherein the multiple sclerosis is a secondary progressive multiple sclerosis (SPMS).

### Claim 5 (depends on 1)

The method of claim 1, wherein the multiple sclerosis is a progressive relapsing multiple sclerosis (PRMS).